Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s hopes of reversing the decline of its renal cell carcinoma (RCC) treatment Inlyta have taken a knock with a failed phase III trial in patients with less advanced disease. ... The ATLAS study was testing whether VEGF inhibitor Inlyta (axitinib)

Latest news

  • Good NICE news for Pfizer, but Dendreon drug rejected Good NICE news for Pfizer, but Dendreon drug rejected

    Good NICE news for Pfizer, but Dendreon drug rejected. Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not. ... NICE has given a final recommendation to Pfizer's new kidney cancer pill Inlyta (axitinib) - but has rejected

  • NICE backs Pfizer drug in kidney cancer NICE backs Pfizer drug in kidney cancer

    NICE backs Pfizer drug in kidney cancer. Inlyta near end of two-year struggle for recommendation. ... Pfizer's Inlyta is finally on course for routine use on the NHS in England and Wales after being recommended in final draft guidance.

  • Pfizer signs $2.85bn immuno-oncology alliance Pfizer signs $2.85bn immuno-oncology alliance

    Earlier this year, Pfizer signed an agreement with Merck &Co to test Keytruda alongside Xalkori (crizotinib) in patients with NSCLC, breast cancer and melanoma candidate palbociclib and Inlyta (axitinib) in patients

  • NHS names drugs to be re-evaluated for Cancer Drugs Fund NHS names drugs to be re-evaluated for Cancer Drugs Fund

    Bosulif (bosutinib). Leukaemia (3 indications). Inlyta (axitinib). Renal cancer. Xalkori (crizotinib).

  • Pfizer and Merck expand anti-PD1 cancer alliance Pfizer and Merck expand anti-PD1 cancer alliance

    types. The two companies are already testing the drug in combination with Pfizer's renal cell carcinoma therapy Inlyta (axitinib) and breast cancer and melanoma candidate palbociclib, a CDK inhibitor that

More from news
Approximately 7 fully matching, plus 23 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Back then, the UK’ s cost-effectiveness watchdog NICE  deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower

  • Oncology drugs under AMNOG

    A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Quick links

Infographics

Multimedia